Takeda’s Experimental Dengue Vaccine Shows Overall Efficacy In Late-Stage Study But Efficacy Varied By Viral Strain

Reuters: Takeda’s dengue vaccine effective overall in study but with major limitation
“Takeda Pharmaceutical Co.’s experimental dengue vaccine was highly effective at preventing the mosquito-borne disease in a late stage study, but it failed to protect against one type of the virus in people with no prior exposure to dengue. Takeda’s vaccine was 80.2% effective at preventing dengue among children and teens in the year after they got the shot, according to results of a Phase III study published in the New England Journal of Medicine on Wednesday…” (Steenhuysen, 11/6).

STAT: A Takeda vaccine for dengue appears effective, but the story is nuanced
“…The late-stage study, published in the New England Journal of Medicine, tested two doses in more than 19,000 children and adolescents in eight countries. Breaking down the results further, though, shows a more nuanced story. In one strain — known as DENV-2 — the effectiveness rate was an impressive 97.7%. But effectiveness in two other strains — DENV-1 and DENV-3 — was much lower, at 73.7% an 62.6%, respectively. There was not enough data to assess the extent to which the vaccine mitigated the fourth strain, known as DENV-4…” (Silverman, 11/6).

Additional coverage of the study is available from NPR and Science.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.